168:
160:
29:
179:. Lymphocyte predominant (LP) ("popcorn") cells are present embedded in nodules consisting of B cells and other reactive cells (mainly reactive T cells). Reed-Sternberg and Hodgkin (RSH) cells are rarely seen, and immunohistochemistry shows a different pattern on the malignant cells; RSH cells typically express CD15 and CD30, whereas LP cells lack expression of these markers, but express B cell markers like CD20, CD22, and CD79a and also express the common leukocyte antigen CD45, which is uncommon on RSH cells. The LP cells have scant cytoplasm and one folded or multilobated nuclei with prominent, mostly basophilic nucleoli. Expert pathology review of multiple morphologic and immunophenotypic features including the use of immunohistochemistry is essential.
257:(radio therapy) may reduce the risk of progression in adults. In one study, stage I-II patients treated with radiation therapy showed 10-year cause-specific survival of 98%, and the rate of developing radiotherapy-related second malignancies was not increased by the treatment (1% after 10 years). A study published in 2013 on large group of patients with early-stage NLPHL indicated support for using limited-field radiation therapy as the sole treatment of early-stage disease. In a study of 1,162 NLPHL patients from the
351:
Prognosis is favourable in comparison with classic HL despite a tendency for disease recurrence requiring long term followup. Relapse can occur at a comparatively late stage in comparison to classic HL. There is limited information regarding the outcome for patients with advanced-stage progression.
342:
optionally followed by radiation therapy is recommended in newly diagnosed late stage disease, while for early stage disease radio therapy alone (stage IA without risk factors) or a brief ABVD-based chemotherapy followed by radiation therapy (early stages other than stage IA without risk factors) was
372:
can occur in up to 12% of cases. After transformation, neoplastic cells carry monoclonal immunoglobulin gene rearrangements. Histological transformation may lead to poor prognosis and therefore repeat biopsy is required at relapse. One study found a transformation rate of 7.6%, and suggested that
285:
has specific use in treatment of NLPHL as it is a chimeric monoclonal antibody against the protein CD20. Studies indicate
Rituximab offers potential in relapsed or refractory patients, and also in front-line treatment especially in advanced stages. Because of a tendency for relapse, maintenance
244:
Surgical lymph node excision may be carried out at the time of diagnosis in certain cases such in children diagnosed at an early stage of progression. One study found sustained complete remission in half of the cases with a watch-and-wait strategy after surgical lymph node excision at the time of
117:
There are small but clear differences in prognosis between the various forms. Lymphocyte predominant HL is an uncommon subtype composed of vague nodules of numerous reactive lymphocytes admixed with large popcorn-shaped RSC. Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are
109:
NLPHL is an uncommon sub-type of
Hodgkin lymphoma, making up 5-10% of Hodgkin lymphomas. It is distinguished from classic Hodgkin lymphoma by the presence of CD20 positive lymphocyte predominant cells, also known as popcorn cells due to their polylobated
1621:
1606:
314:/ABV in children suggested positive results with chemotherapy alone are possible without the need for radiation therapy. Optimal chemotherapy is a topic for debate, for example there is evidence of support for treatment with
261:, radiation therapy improved overall survival and disease specific survival. Recent management strategies recommend that Stage IA NLPHL without clinical risk factors should be treated with limited-field radiotherapy alone.
2566:
224:
Guidelines for
Patients is available, while the NCCN Clinical Practice Guidelines in Oncology provides a reference for clinicians. Any proposed therapeutic strategy must have minimal acute and long-term toxicities.
2310:
1447:"Impact of Low-Dose Involved-Field Radiation Therapy on Pediatric Patients with Lymphocyte-Predominant Hodgkin Lymphoma Treated with Chemotherapy: A Report from the Children's Oncology Group"
1864:
167:
159:
1981:
1636:
2571:
28:
2380:
1278:"Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis"
2594:
2336:
382:
1675:
2026:
2539:
258:
2578:
2124:
1869:
2003:
1346:"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)"
404:"Molecular Cytogenetic Analyses of Immunoglobulin Loci in Nodular Lymphocyte Predominant Hodgkin's Lymphoma Reveal a Recurrent IGH-BCL6 Juxtaposition"
2104:
1902:
779:"A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma"
286:
treatment such as every 6 months for 2 years is suggested. Rituximab has been shown to improve patient outcomes after histological transformation.
2528:
2202:
1756:
2375:
2194:
1745:
221:
171:
Hodgkin lymphoma, nodular lymphocyte predominant (high power view). Notice the presence of LP cells, also known as "popcorn cells". (H&E)
2523:
1010:"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis"
163:
Hodgkin lymphoma, nodular lymphocyte predominant (low power view). Notice the nodular architecture and the areas of "mottling". (H&E)
2479:
2099:
1897:
1781:
2370:
889:"Early-Stage, Lymphocyte-Predominant Hodgkin's Lymphoma: Patient Outcomes From a Large, Single-Institution Series With Long Follow-Up"
727:"Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma"
1668:
453:"The importance of follow-up biopsies of clinically suspicious lymphadenopathy in nodular lymphocyte predominant Hodgkin's lymphoma"
1540:"Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base"
1319:"Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment"
373:
prior exposure to chemotherapy and a presentation with splenic involvement were associated with increased risks of transformation.
2331:
322:, results showing high rates (40%) of relapse after 10 years since ABVD chemotherapy. BEACOPP has higher reported toxicity risk.
1398:"Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution"
1125:
2561:
2553:
2412:
2290:
2229:
2215:
2109:
2050:
1887:
1813:
1216:"Long-Term Outcomes in Patients with Early Stage Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Treated with Radiotherapy"
833:"Nodular Lymphocyte Predominant Hodgkin Lymphoma versus T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Diagnostic Challenge"
1140:
2609:
2519:
2469:
2365:
2094:
1878:
369:
360:
One study in the United States has suggested improved overall survival in response to chemotherapy for
African Americans.
2501:
2407:
2390:
2198:
1752:
1661:
183:
2442:
2315:
2021:
1124:
NCCN Guidelines for
Patients : NCCN Quick Guide. Hodgkin Lymphoma (Nodular Lymphocyte-Predominant HL Treatment)
274:
2357:
2635:
2245:
2086:
2008:
2447:
2275:
656:
1913:
47:
2464:
2015:
2341:
2320:
2234:
695:
452:
777:
Strobbe L, Valke LL, Diets IJ, van den Brand M, Aben K, Raemaekers KJ, Hebeda KM, van
Krieken JH (2016).
2473:
2063:
1957:
2036:
1859:
655:
Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA (2011).
599:
2270:
1882:
1793:
1227:
929:
1318:
2070:
1854:
1824:
1625:
1277:
1167:"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study"
339:
315:
311:
307:
236:(watch and wait) is defined as a period of observation of at least 3 months without any treatment.
2534:
1569:
1375:
1107:
1039:
637:
549:"Lymphocyte-Predominant Hodgkin's Disease in Children: A Case Study and Review of the Literature"
485:
Wang, Hao-Wei; Balakrishna, Jayalakshmi P; Pittaluga, Stefania; Jaffe, Elaine S. (January 2019).
967:
2614:
2284:
2265:
2254:
2044:
1934:
1849:
1561:
1520:
1476:
1427:
1367:
1299:
1255:
1196:
1099:
1031:
949:
910:
864:
808:
748:
707:
676:
629:
621:
580:
524:
506:
464:
433:
331:
254:
193:
92:
59:
2384:
2163:
2031:
1930:
1653:
1551:
1510:
1466:
1458:
1417:
1409:
1357:
1326:
1289:
1245:
1235:
1186:
1178:
1089:
1021:
941:
900:
854:
844:
798:
790:
738:
668:
611:
570:
560:
514:
498:
423:
415:
233:
176:
99:
1126:
https://www.nccn.org/patients/guidelines/quick_guides/hodgkin/nodular_treatment/index.html#
696:"Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma"
2157:
2152:
1961:
1845:
1711:
1706:
1144:
1231:
2604:
1641:
1471:
1446:
1422:
1397:
1250:
1215:
1191:
1166:
859:
832:
803:
778:
575:
548:
519:
486:
428:
403:
1630:
419:
2629:
2511:
2210:
2119:
2075:
1892:
1766:
641:
295:
1573:
1111:
2114:
1776:
1379:
134:
has been used in lymphocyte predominant
Hodgkin lymphoma with encouraging results.
111:
1330:
182:
Tumors generally located in the peripheral lymph nodes, which can be detected via
51:
1515:
1498:
1413:
1362:
1345:
1294:
1240:
1182:
1137:
1043:
1026:
1009:
930:"Nodular Lymphocyte Predominant Hodgkin Lymphoma: Diagnostic Pearls and Pitfalls"
1788:
743:
726:
672:
1684:
1615:
794:
148:
64:
40:
36:
905:
888:
625:
616:
510:
335:
282:
278:
131:
1565:
1524:
1480:
1431:
1371:
1303:
1259:
1200:
1103:
1035:
953:
945:
914:
868:
812:
752:
711:
680:
633:
584:
528:
468:
437:
849:
565:
2599:
2427:
2138:
1701:
1688:
270:
259:
Surveillance, Epidemiology and End
Results (SEER) cancer registry program
68:
1598:
196:
is used to classify tumors and symptoms. Stage IV disease is very rare.
1556:
1539:
1094:
1077:
303:
187:
1462:
1445:
Appel BE, Chen L, Buxton A, Wolden SL, Hodgson DC, Nachman JB (2012).
502:
2147:
1610:
103:
43:
694:
Wlodarska I, Stul M, De Wolf-Peeters C, Hagemeijer A (August 2004).
212:
Diagnosis usually occurs at an early stage of disease progression.
1970:
1835:
1819:
166:
158:
50:
variant that has a popcorn-shaped nucleus (left-bottom of image).
46:
showing nodular lymphocyte predominant
Hodgkin lymphoma, with the
1165:
Lazarovici J, Dartigues P, Brice P, et al. (December 2015).
402:
Renné C, Martín-Subero JI, Hansmann ML, Siebert R (August 2005).
2433:
2327:
2306:
2224:
1966:
1941:
1921:
1917:
1804:
1722:
1717:
319:
299:
137:
127:
123:
119:
95:
1657:
2173:
2168:
2058:
600:"How I treat nodular lymphocyte-predominant Hodgkin lymphoma"
657:"Rituximab in Hodgkin lymphoma: Is the target always a hit?"
2311:
Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
725:
Wlodarska I, Nooyen P, Maes B, et al. (January 2003).
1396:
Kenderian SS, Habermann TM, Macon WR, et al. (2016).
1076:
Biasoli I, Stamatoullas A, Meignin V, et al. (2010).
1344:
Schulz H, Rehwald U, Morschhauser F, et al. (2008).
451:
Achten R, Verhoef G, De Wolf-Peeters C (December 2003).
1492:
1490:
1003:
1001:
999:
997:
995:
993:
991:
989:
987:
1214:
Solanki AA, LeMieux MH, Chiu BC, et al. (2013).
598:
Eichenauer, Dennis A.; Engert, Andreas (2020-12-24).
1588:
2587:
2552:
2510:
2492:
2456:
2426:
2399:
2354:
2299:
2253:
2244:
2184:
2146:
2137:
2085:
1995:
1956:
1912:
1834:
1803:
1765:
1744:
1733:
1700:
1592:
140:gene rearrangements have been frequently observed.
74:
58:
21:
2381:Peripheral T-cell lymphoma not otherwise specified
1276:Gerber NK, Atoria CL, Elkin EB, Yahalom J (2015).
1078:"Nodular, lymphocyte-predominant Hodgkin lymphoma"
2203:Precursor T acute lymphoblastic leukemia/lymphoma
1757:Precursor B acute lymphoblastic leukemia/lymphoma
487:"Diagnosis of Hodgkin Lymphoma in the Modern Era"
204:There is a male predominance of NLPHL diagnosis.
1008:Xing KH, Connors JM, Lai A, et al. (2014).
1947:Nodular lymphocyte predominant Hodgkin lymphoma
1391:
1389:
1271:
1269:
1160:
1158:
1156:
1154:
1152:
934:Archives of Pathology & Laboratory Medicine
882:
880:
878:
85:Nodular lymphocyte predominant Hodgkin lymphoma
22:Nodular lymphocyte predominant Hodgkin lymphoma
1138:http://williams.medicine.wisc.edu/hodgkins.pdf
772:
770:
768:
766:
764:
762:
542:
540:
538:
383:Progressive transformation of germinal centers
126:negative while positive for the B cell marker
2337:Secondary cutaneous CD30+ large-cell lymphoma
1669:
1071:
1069:
1067:
1065:
1063:
1061:
1059:
1057:
1055:
1053:
887:Chen RC, Chin MS, Ng AK, et al. (2010).
826:
824:
822:
8:
2027:Post-transplant lymphoproliferative disorder
1982:immunoproliferative immunoglobulin disorders
480:
478:
2540:Diffuse infiltrative lymphocytosis syndrome
2579:Jessner lymphocytic infiltrate of the skin
2250:
2181:
2143:
2125:Primary cutaneous follicle center lymphoma
1870:Primary cutaneous follicle center lymphoma
1741:
1730:
1697:
1676:
1662:
1654:
1589:
1538:Olszewski AJ, Shrestha R, Cook NM (2015).
27:
18:
1555:
1514:
1499:"R-CHOP in NLPHL: who should receive it?"
1470:
1421:
1361:
1293:
1249:
1239:
1190:
1136:NCCN Guidelines v2.2014 Hodgkin Lymphoma
1093:
1025:
904:
858:
848:
802:
742:
615:
574:
564:
518:
427:
175:The characteristics of NLPHL differ from
2105:Primary cutaneous marginal zone lymphoma
1903:Primary cutaneous marginal zone lymphoma
2567:with bandlike and perivascular patterns
2529:Autoimmune lymphoproliferative syndrome
394:
2376:Enteropathy-associated T-cell lymphoma
370:diffuse large B-cell lymphoma (DLBCL)
7:
2524:X-linked lymphoproliferative disease
1317:Eichenauer, DA; Hartmann, S (2023).
553:Case Reports in Oncological Medicine
130:. The anti-CD20 monoclonal antibody
2480:Large granular lymphocytic leukemia
2100:Intravascular large B-cell lymphoma
102:, a cancer of the immune system's
14:
1497:Eichenauer DA, Engert A (2017).
177:classical Hodgkin lymphoma (cHL)
2332:CD30+ cutaneous T-cell lymphoma
1282:Int J Radiation Oncol Biol Phys
78:0.1-0.2 cases / 100000 per year
2562:Cutaneous lymphoid hyperplasia
2554:Cutaneous lymphoid hyperplasia
2413:Adult T-cell leukemia/lymphoma
2291:Adult T-cell leukemia/lymphoma
2230:Anaplastic large-cell lymphoma
2110:Primary cutaneous immunocytoma
2051:Splenic marginal zone lymphoma
831:Rets AV, Gottesman SR (2014).
491:British Journal of Haematology
220:A treatment guide provided by
1:
2610:Lymphoproliferative disorders
2520:Lymphoproliferative disorders
2470:Extranodal NK-T-cell lymphoma
2342:Lymphomatoid papulosis type A
2321:Lymphomatoid papulosis type B
2235:Lymphomatoid papulosis type A
2095:Diffuse large B-cell lymphoma
1331:10.1080/17474086.2023.2226859
547:Stier JR, Vasquez RJ (2015).
420:10.1016/S1525-1578(10)60564-8
368:Histologic transformation to
334:(radio therapy) and antibody
298:-containing regimens include
2502:Acute biphenotypic leukaemia
2391:Subcutaneous T-cell lymphoma
1516:10.1182/blood-2017-05-786301
1414:10.1182/blood-2015-08-665505
1363:10.1182/blood-2007-03-078725
1295:10.1016/j.ijrobp.2015.02.012
1241:10.1371/journal.pone.0075336
1183:10.3324/haematol.2015.133025
1027:10.1182/blood-2013-12-541078
893:Journal of Clinical Oncology
330:One study reported combined
2443:Aggressive NK-cell leukemia
2316:Pleomorphic T-cell lymphoma
2022:Lymphomatoid granulomatosis
1323:Expert Review of Hematology
364:Histological transformation
310:. Results of a trial with
114:, which look like popcorn.
2652:
744:10.1182/blood-2002-05-1592
673:10.1016/j.ctrv.2010.11.005
1696:
795:10.1007/s00277-015-2578-6
294:Possible options such as
35:
26:
2595:Hematological malignancy
2448:Blastic NK cell lymphoma
2276:Granulomatous slack skin
2032:Classic Hodgkin lymphoma
1931:Classic Hodgkin lymphoma
906:10.1200/JCO.2009.24.0945
617:10.1182/blood.2019004044
946:10.5858/2010-0207-OA.1
253:Studies indicate that
172:
164:
2474:Angiocentric lymphoma
2064:AIDS-related lymphoma
1888:Splenic marginal zone
972:pathologyoutlines.com
170:
162:
2572:with nodular pattern
2271:Pagetoid reticulosis
1883:marginal zone B-cell
1451:Pediatr Blood Cancer
2071:Helicobacter pylori
1898:Nodal marginal zone
1825:Hairy cell leukemia
1691:and related disease
1232:2013PLoSO...875336S
968:"Pathology Outline"
850:10.1155/2014/956217
566:10.1155/2015/351431
48:Reed–Sternberg cell
2615:Lymphoid leukemias
2535:Leukemoid reaction
2371:Angioimmunoblastic
2037:Burkitt's lymphoma
1557:10.1002/cncr.29527
1143:2020-07-09 at the
1095:10.1002/cncr.24819
326:Combined treatment
173:
165:
144:Signs and symptoms
2623:
2622:
2548:
2547:
2488:
2487:
2422:
2421:
2350:
2349:
2266:Mycosis fungoides
2133:
2132:
1991:
1990:
1935:Nodular sclerosis
1850:follicular B cell
1651:
1650:
1463:10.1002/pbc.24258
1408:(16): 1960–1966.
1177:(12): 1579–1586.
1020:(23): 3567–3573.
940:(10): 1434–1439.
928:Smith LB (2010).
610:(26): 2987–2993.
503:10.1111/bjh.15614
332:radiation therapy
255:radiation therapy
249:Radiation therapy
240:Surgical excision
194:Ann Arbor staging
98:positive form of
82:
81:
16:Medical condition
2643:
2636:Hodgkin lymphoma
2385:Lennert lymphoma
2251:
2182:
2144:
2009:Primary effusion
1742:
1731:
1698:
1678:
1671:
1664:
1655:
1590:
1578:
1577:
1559:
1535:
1529:
1528:
1518:
1494:
1485:
1484:
1474:
1457:(7): 1284–1289.
1442:
1436:
1435:
1425:
1393:
1384:
1383:
1365:
1341:
1335:
1334:
1314:
1308:
1307:
1297:
1273:
1264:
1263:
1253:
1243:
1211:
1205:
1204:
1194:
1162:
1147:
1134:
1128:
1122:
1116:
1115:
1097:
1073:
1048:
1047:
1029:
1005:
982:
981:
979:
978:
964:
958:
957:
925:
919:
918:
908:
884:
873:
872:
862:
852:
828:
817:
816:
806:
774:
757:
756:
746:
722:
716:
715:
691:
685:
684:
661:Cancer Treat Rev
652:
646:
645:
619:
595:
589:
588:
578:
568:
544:
533:
532:
522:
482:
473:
472:
448:
442:
441:
431:
399:
234:Watchful waiting
229:Watchful waiting
100:Hodgkin lymphoma
31:
19:
2651:
2650:
2646:
2645:
2644:
2642:
2641:
2640:
2626:
2625:
2624:
2619:
2583:
2544:
2506:
2494:
2484:
2452:
2431:
2418:
2395:
2356:
2346:
2295:
2240:
2188:
2186:
2161:
2156:
2150:
2129:
2081:
1987:
1964:
1952:
1908:
1846:germinal center
1830:
1799:
1761:
1737:
1735:
1715:
1710:
1704:
1692:
1682:
1652:
1647:
1646:
1601:
1587:
1582:
1581:
1550:(19): 3472–80.
1537:
1536:
1532:
1496:
1495:
1488:
1444:
1443:
1439:
1395:
1394:
1387:
1343:
1342:
1338:
1316:
1315:
1311:
1275:
1274:
1267:
1213:
1212:
1208:
1164:
1163:
1150:
1145:Wayback Machine
1135:
1131:
1123:
1119:
1075:
1074:
1051:
1007:
1006:
985:
976:
974:
966:
965:
961:
927:
926:
922:
886:
885:
876:
843:(956217): 1–5.
837:Case Rep Pathol
830:
829:
820:
776:
775:
760:
724:
723:
719:
693:
692:
688:
654:
653:
649:
597:
596:
592:
546:
545:
536:
484:
483:
476:
450:
449:
445:
401:
400:
396:
391:
379:
366:
358:
349:
328:
292:
267:
251:
242:
231:
218:
210:
208:Early detection
202:
157:
146:
17:
12:
11:
5:
2649:
2647:
2639:
2638:
2628:
2627:
2621:
2620:
2618:
2617:
2612:
2607:
2605:Leukemia cutis
2602:
2597:
2591:
2589:
2585:
2584:
2582:
2581:
2576:
2575:
2574:
2569:
2558:
2556:
2550:
2549:
2546:
2545:
2543:
2542:
2537:
2532:
2526:
2516:
2514:
2508:
2507:
2505:
2504:
2498:
2496:
2490:
2489:
2486:
2485:
2483:
2482:
2477:
2460:
2458:
2454:
2453:
2451:
2450:
2445:
2439:
2437:
2424:
2423:
2420:
2419:
2417:
2416:
2403:
2401:
2397:
2396:
2394:
2393:
2388:
2378:
2373:
2368:
2362:
2360:
2352:
2351:
2348:
2347:
2345:
2344:
2339:
2334:
2324:
2323:
2318:
2313:
2303:
2301:
2297:
2296:
2294:
2293:
2285:Sézary disease
2279:
2278:
2273:
2268:
2259:
2257:
2248:
2242:
2241:
2239:
2238:
2232:
2220:
2219:
2216:Prolymphocytic
2206:
2192:
2190:
2179:
2178:
2177:
2171:
2141:
2135:
2134:
2131:
2130:
2128:
2127:
2122:
2117:
2112:
2107:
2102:
2097:
2091:
2089:
2083:
2082:
2080:
2079:
2067:
2055:
2054:
2053:
2041:
2040:
2039:
2034:
2029:
2024:
2012:
1999:
1997:
1993:
1992:
1989:
1988:
1986:
1985:
1976:
1974:
1954:
1953:
1951:
1950:
1938:
1927:
1925:
1910:
1909:
1907:
1906:
1900:
1895:
1890:
1874:
1873:
1867:
1862:
1857:
1841:
1839:
1832:
1831:
1829:
1828:
1816:
1814:Prolymphocytic
1810:
1808:
1801:
1800:
1798:
1797:
1785:
1772:
1770:
1763:
1762:
1760:
1750:
1748:
1739:
1728:
1727:
1726:
1694:
1693:
1683:
1681:
1680:
1673:
1666:
1658:
1649:
1648:
1645:
1644:
1633:
1618:
1602:
1597:
1596:
1594:
1593:Classification
1586:
1585:External links
1583:
1580:
1579:
1530:
1509:(4): 387–388.
1486:
1437:
1385:
1336:
1309:
1265:
1206:
1148:
1129:
1117:
1088:(3): 631–639.
1049:
983:
959:
920:
899:(1): 136–141.
874:
818:
789:(3): 417–423.
758:
717:
686:
647:
590:
534:
474:
463:(12): 1431–2.
443:
393:
392:
390:
387:
386:
385:
378:
375:
365:
362:
357:
354:
348:
345:
327:
324:
291:
288:
266:
263:
250:
247:
241:
238:
230:
227:
217:
214:
209:
206:
201:
198:
156:
153:
151:are uncommon.
145:
142:
80:
79:
76:
72:
71:
62:
56:
55:
33:
32:
24:
23:
15:
13:
10:
9:
6:
4:
3:
2:
2648:
2637:
2634:
2633:
2631:
2616:
2613:
2611:
2608:
2606:
2603:
2601:
2598:
2596:
2593:
2592:
2590:
2586:
2580:
2577:
2573:
2570:
2568:
2565:
2564:
2563:
2560:
2559:
2557:
2555:
2551:
2541:
2538:
2536:
2533:
2530:
2527:
2525:
2521:
2518:
2517:
2515:
2513:
2512:Lymphocytosis
2509:
2503:
2500:
2499:
2497:
2491:
2481:
2478:
2475:
2471:
2467:
2466:
2462:
2461:
2459:
2455:
2449:
2446:
2444:
2441:
2440:
2438:
2435:
2429:
2425:
2414:
2410:
2409:
2405:
2404:
2402:
2398:
2392:
2389:
2386:
2382:
2379:
2377:
2374:
2372:
2369:
2367:
2366:Hepatosplenic
2364:
2363:
2361:
2359:
2353:
2343:
2340:
2338:
2335:
2333:
2329:
2326:
2325:
2322:
2319:
2317:
2314:
2312:
2308:
2305:
2304:
2302:
2298:
2292:
2289:
2288:
2287:
2286:
2283:
2277:
2274:
2272:
2269:
2267:
2264:
2261:
2260:
2258:
2256:
2252:
2249:
2247:
2243:
2236:
2233:
2231:
2227:
2226:
2222:
2221:
2217:
2213:
2212:
2211:prolymphocyte
2208:
2207:
2204:
2200:
2196:
2193:
2191:
2183:
2180:
2175:
2172:
2170:
2167:
2166:
2165:
2159:
2154:
2149:
2145:
2142:
2140:
2136:
2126:
2123:
2121:
2120:Plasmacytosis
2118:
2116:
2113:
2111:
2108:
2106:
2103:
2101:
2098:
2096:
2093:
2092:
2090:
2088:
2084:
2077:
2076:MALT lymphoma
2073:
2072:
2068:
2065:
2061:
2060:
2056:
2052:
2049:
2048:
2047:
2046:
2042:
2038:
2035:
2033:
2030:
2028:
2025:
2023:
2020:
2019:
2018:
2017:
2013:
2010:
2006:
2005:
2001:
2000:
1998:
1994:
1984:
1983:
1978:
1977:
1975:
1972:
1968:
1963:
1959:
1955:
1948:
1944:
1943:
1939:
1936:
1932:
1929:
1928:
1926:
1923:
1919:
1915:
1911:
1904:
1901:
1899:
1896:
1894:
1891:
1889:
1885:
1884:
1880:
1879:marginal zone
1876:
1875:
1871:
1868:
1866:
1863:
1861:
1858:
1856:
1852:
1851:
1847:
1843:
1842:
1840:
1837:
1833:
1826:
1822:
1821:
1817:
1815:
1812:
1811:
1809:
1806:
1802:
1795:
1791:
1790:
1786:
1783:
1779:
1778:
1774:
1773:
1771:
1768:
1764:
1758:
1754:
1751:
1749:
1747:
1743:
1740:
1732:
1729:
1724:
1721:
1720:
1719:
1713:
1708:
1703:
1699:
1695:
1690:
1686:
1679:
1674:
1672:
1667:
1665:
1660:
1659:
1656:
1643:
1639:
1638:
1634:
1632:
1628:
1627:
1623:
1619:
1617:
1613:
1612:
1608:
1604:
1603:
1600:
1595:
1591:
1584:
1575:
1571:
1567:
1563:
1558:
1553:
1549:
1545:
1541:
1534:
1531:
1526:
1522:
1517:
1512:
1508:
1504:
1500:
1493:
1491:
1487:
1482:
1478:
1473:
1468:
1464:
1460:
1456:
1452:
1448:
1441:
1438:
1433:
1429:
1424:
1419:
1415:
1411:
1407:
1403:
1399:
1392:
1390:
1386:
1381:
1377:
1373:
1369:
1364:
1359:
1356:(1): 109–11.
1355:
1351:
1347:
1340:
1337:
1332:
1328:
1324:
1320:
1313:
1310:
1305:
1301:
1296:
1291:
1287:
1283:
1279:
1272:
1270:
1266:
1261:
1257:
1252:
1247:
1242:
1237:
1233:
1229:
1226:(9): e75336.
1225:
1221:
1217:
1210:
1207:
1202:
1198:
1193:
1188:
1184:
1180:
1176:
1172:
1171:Haematologica
1168:
1161:
1159:
1157:
1155:
1153:
1149:
1146:
1142:
1139:
1133:
1130:
1127:
1121:
1118:
1113:
1109:
1105:
1101:
1096:
1091:
1087:
1083:
1079:
1072:
1070:
1068:
1066:
1064:
1062:
1060:
1058:
1056:
1054:
1050:
1045:
1041:
1037:
1033:
1028:
1023:
1019:
1015:
1011:
1004:
1002:
1000:
998:
996:
994:
992:
990:
988:
984:
973:
969:
963:
960:
955:
951:
947:
943:
939:
935:
931:
924:
921:
916:
912:
907:
902:
898:
894:
890:
883:
881:
879:
875:
870:
866:
861:
856:
851:
846:
842:
838:
834:
827:
825:
823:
819:
814:
810:
805:
800:
796:
792:
788:
784:
780:
773:
771:
769:
767:
765:
763:
759:
754:
750:
745:
740:
737:(2): 706–10.
736:
732:
728:
721:
718:
713:
709:
706:(8): 965–72.
705:
701:
700:Haematologica
697:
690:
687:
682:
678:
674:
670:
667:(5): 385–90.
666:
662:
658:
651:
648:
643:
639:
635:
631:
627:
623:
618:
613:
609:
605:
601:
594:
591:
586:
582:
577:
572:
567:
562:
558:
554:
550:
543:
541:
539:
535:
530:
526:
521:
516:
512:
508:
504:
500:
496:
492:
488:
481:
479:
475:
470:
466:
462:
458:
457:Haematologica
454:
447:
444:
439:
435:
430:
425:
421:
417:
413:
409:
405:
398:
395:
388:
384:
381:
380:
376:
374:
371:
363:
361:
355:
353:
346:
344:
341:
337:
333:
325:
323:
321:
317:
313:
309:
305:
301:
297:
296:anthracycline
289:
287:
284:
280:
276:
275:immunotherapy
272:
265:Immunotherapy
264:
262:
260:
256:
248:
246:
239:
237:
235:
228:
226:
223:
215:
213:
207:
205:
199:
197:
195:
191:
189:
185:
180:
178:
169:
161:
154:
152:
150:
143:
141:
139:
135:
133:
129:
125:
121:
115:
113:
107:
105:
101:
97:
94:
90:
86:
77:
73:
70:
66:
63:
61:
57:
53:
52:H&E stain
49:
45:
42:
38:
34:
30:
25:
20:
2463:
2406:
2400:By infection
2281:
2280:
2262:
2223:
2209:
2187:development/
2115:Plasmacytoma
2069:
2057:
2043:
2014:
2002:
1996:By infection
1979:
1946:
1940:
1877:
1844:
1818:
1787:
1777:naive B cell
1775:
1736:development/
1635:
1620:
1605:
1547:
1543:
1533:
1506:
1502:
1454:
1450:
1440:
1405:
1401:
1353:
1349:
1339:
1322:
1312:
1288:(1): 76–83.
1285:
1281:
1223:
1219:
1209:
1174:
1170:
1132:
1120:
1085:
1081:
1017:
1013:
975:. Retrieved
971:
962:
937:
933:
923:
896:
892:
840:
836:
786:
782:
734:
730:
720:
703:
699:
689:
664:
660:
650:
607:
603:
593:
556:
552:
497:(1): 45–59.
494:
490:
460:
456:
446:
414:(3): 352–6.
411:
407:
397:
367:
359:
350:
329:
293:
290:Chemotherapy
268:
252:
243:
232:
219:
211:
203:
192:
181:
174:
147:
136:
116:
108:
93:slow-growing
88:
84:
83:
2282:aggressive:
2255:MF+variants
1794:Mantle cell
1789:mantle zone
783:Ann Hematol
408:J Mol Diagn
318:instead of
273:for use in
269:An example
245:diagnosis.
2358:peripheral
1855:Follicular
1685:Leukaemias
977:2017-09-02
559:: 351431.
389:References
216:Management
149:B symptoms
65:Hematology
41:lymph node
37:Micrograph
2493:Lymphoid+
2263:indolent:
2246:Cutaneous
2087:Cutaneous
1865:GCB DLBCL
1860:Burkitt's
1689:lymphomas
642:221476874
626:0006-4971
511:0007-1048
356:Ethnicity
347:Prognosis
343:advised.
336:Rituximab
283:Rituximab
279:Rituximab
155:Diagnosis
132:Rituximab
75:Frequency
60:Specialty
2630:Category
2600:leukemia
2158:leukemia
2153:lymphoma
1712:leukemia
1707:lymphoma
1574:45005554
1566:26149294
1525:28751354
1481:22847767
1432:26837698
1372:17938252
1304:25863756
1260:24058675
1220:PLOS ONE
1201:26430172
1141:Archived
1112:25570848
1104:20029973
1036:24713929
954:20923296
915:19933914
869:25110597
813:26732883
753:12393409
712:15339680
681:21183282
634:32877522
585:25878913
529:30407610
469:14688002
438:16049307
377:See also
271:antibody
184:PET scan
69:oncology
2588:General
2495:myeloid
2457:T or NK
2428:NK cell
1782:CLL/SLL
1642:M9659/3
1472:3468707
1423:4841039
1380:9934281
1251:3776776
1228:Bibcode
1192:4666334
860:4109592
804:4742486
576:4388010
520:6310079
429:1867541
304:BEACOPP
188:CT scan
104:B cells
91:) is a
2432:(most
2408:HTLV-1
2300:Non-MF
2189:marker
2162:(most
2148:T cell
1820:CD11c+
1738:marker
1716:(most
1702:B cell
1572:
1564:
1544:Cancer
1523:
1479:
1469:
1430:
1420:
1378:
1370:
1302:
1258:
1248:
1199:
1189:
1110:
1102:
1082:Cancer
1042:
1034:
952:
913:
867:
857:
811:
801:
751:
710:
679:
640:
632:
624:
583:
573:
527:
517:
509:
467:
436:
426:
340:R-CHOP
316:R-CHOP
112:nuclei
44:biopsy
2355:Other
2225:CD30+
1971:CD138
1942:CD20+
1836:CD79a
1637:ICD-O
1631:201.9
1616:C81.0
1570:S2CID
1503:Blood
1402:Blood
1376:S2CID
1350:Blood
1108:S2CID
1044:25058
1040:S2CID
1014:Blood
895:. 1.
731:Blood
638:S2CID
604:Blood
89:NLPHL
39:of a
2434:CD56
2328:CD30
2307:CD30
2195:TdT+
2139:T/NK
2004:KSHV
1980:see
1967:CD38
1958:PCDs
1922:CD30
1918:CD15
1893:MALT
1805:CD22
1746:TdT+
1723:CD20
1718:CD19
1626:9-CM
1562:PMID
1521:PMID
1477:PMID
1428:PMID
1368:PMID
1300:PMID
1256:PMID
1197:PMID
1100:PMID
1032:PMID
950:PMID
911:PMID
865:PMID
841:2014
809:PMID
749:PMID
708:PMID
677:PMID
630:PMID
622:ISSN
581:PMID
557:2015
525:PMID
507:ISSN
465:PMID
434:PMID
320:ABVD
312:COPP
308:CHOP
306:and
300:ABVD
222:NCCN
186:and
138:BCL6
128:CD20
124:CD30
122:and
120:CD15
96:CD20
67:and
2465:EBV
2330:+:
2309:-:
2199:ALL
2174:CD8
2169:CD4
2164:CD3
2059:HIV
2045:HCV
2016:EBV
1920:+,
1767:CD5
1753:ALL
1622:ICD
1607:ICD
1552:doi
1548:121
1511:doi
1507:130
1467:PMC
1459:doi
1418:PMC
1410:doi
1406:127
1358:doi
1354:111
1327:doi
1290:doi
1246:PMC
1236:doi
1187:PMC
1179:doi
1175:100
1090:doi
1086:116
1022:doi
1018:123
942:doi
938:134
901:doi
855:PMC
845:doi
799:PMC
791:doi
739:doi
735:101
669:doi
612:doi
608:136
571:PMC
561:doi
515:PMC
499:doi
495:184
424:PMC
416:doi
338:.
277:is
200:Sex
2632::
2197::
2185:By
1973:+)
1969:+/
1962:PP
1924:+)
1914:RS
1734:By
1687:,
1640::
1629::
1614::
1611:10
1568:.
1560:.
1546:.
1542:.
1519:.
1505:.
1501:.
1489:^
1475:.
1465:.
1455:59
1453:.
1449:.
1426:.
1416:.
1404:.
1400:.
1388:^
1374:.
1366:.
1352:.
1348:.
1325:.
1321:.
1298:.
1286:92
1284:.
1280:.
1268:^
1254:.
1244:.
1234:.
1222:.
1218:.
1195:.
1185:.
1173:.
1169:.
1151:^
1106:.
1098:.
1084:.
1080:.
1052:^
1038:.
1030:.
1016:.
1012:.
986:^
970:.
948:.
936:.
932:.
909:.
897:28
891:.
877:^
863:.
853:.
839:.
835:.
821:^
807:.
797:.
787:95
785:.
781:.
761:^
747:.
733:.
729:.
704:89
702:.
698:.
675:.
665:37
663:.
659:.
636:.
628:.
620:.
606:.
602:.
579:.
569:.
555:.
551:.
537:^
523:.
513:.
505:.
493:.
489:.
477:^
461:88
459:.
455:.
432:.
422:.
410:.
406:.
302:,
281:.
190:.
106:.
2531:)
2522:(
2476:)
2472:/
2468:(
2436:)
2430:/
2415:)
2411:(
2387:)
2383:(
2237:)
2228:(
2218:)
2214:(
2205:)
2201:(
2176:)
2160:)
2155:,
2151:(
2078:)
2074:(
2066:)
2062:(
2011:)
2007:(
1965:(
1960:/
1949:)
1945:(
1937:)
1933:(
1916:(
1905:)
1886:(
1881:/
1872:)
1853:(
1848:/
1838:+
1827:)
1823:(
1807:+
1796:)
1792:(
1784:)
1780:(
1769:+
1759:)
1755:(
1725:)
1714:)
1709:,
1705:(
1677:e
1670:t
1663:v
1624:-
1609:-
1599:D
1576:.
1554::
1527:.
1513::
1483:.
1461::
1434:.
1412::
1382:.
1360::
1333:.
1329::
1306:.
1292::
1262:.
1238::
1230::
1224:8
1203:.
1181::
1114:.
1092::
1046:.
1024::
980:.
956:.
944::
917:.
903::
871:.
847::
815:.
793::
755:.
741::
714:.
683:.
671::
644:.
614::
587:.
563::
531:.
501::
471:.
440:.
418::
412:7
87:(
54:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
